The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study

I. Davidson, H. Beardsell, B. Smith, S. Mandalia, M. Bower, B. Gazzard, M. Nelson, J. Stebbing*

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Background: We investigated the reasons for switching antiretroviral regimens, an issue rarely addressed in cohort studies. Methods: An observed toxicity switch rate (OTSR) was calculated by Poisson regression using the number of days individuals received each individual antiretroviral drug. Results: Of 3333 individuals receiving HAART, a total of 14% of regimens were switched, the majority occurring after 6 months of therapy. Toxicity was the major reason for switching (61%) and there were no major statistically significant differences in OTSR between the protease inhibitor (OTSR 26.4, 95% CI 18.3-37) and non-nucleoside reverse transcriptase inhibitor (OTSR 22.2, 95% CI 13.6-34.4) based regimes. For individual antiretrovirals, stavudine and zidovudine had significantly higher " switch" scores than all other drugs. Conclusions: There were no differences between the major HAART classes in OTSR. We suggest that newer antiretrovirals will require differentiation in terms of longer-term toxicity, as this is the major reason for switching.

Original languageEnglish (US)
Pages (from-to)227-229
Number of pages3
JournalAntiviral Research
Volume86
Issue number2
DOIs
StatePublished - May 1 2010

Keywords

  • Adherence
  • Antiretroviral
  • Compliance
  • HAART
  • Switching
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study'. Together they form a unique fingerprint.

  • Cite this